CoChat

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study: Reversibility of PN with VMP in newly diagnosed MM

Dimopoulos, Meletios A., Mateos, Maria-Victoria, Richardson, Paul G., Schlag, Rudolf, Khuageva, Nuriet K., Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Palumbo, Antonio, Wu, Ka Lung, Esseltine, Dixie-Lee, Liu, Kevin, Deraedt, William, Cakana, Andrew, Van De Velde, Helgi, San Miguel, Jesús F. · 2011 · European Journal of Haematology
Cited by 142

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone. METHODS: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m(2), days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, and days 1, 8, 22, 29, cycles 5-9; melphalan 9 mg/m(2), days 1-4, cycles 1-9; and prednisone 60 mg/m(2), days 1-4, cycles 1-9). RESULTS: Overall, 47% of patients receiving VMP developed PN, including 19% grade 2 and 13% grade ≥ 3 (<1% grade 4). The PN incidence was dose-related and reached a plateau at a cumulative bortezomib dose of approximately 45 mg/m(2). Median time to PN onset was 2.3 months. Bortezomib-associated PN was reversible; 79% of events improved by at least one NCI CTCAE grade within a median of 1.9 months and 60% completely resolved within a median of 5.7 months, with reversibility similar in responding and non-responding patients. By multivariate analysis, baseline neuropathy was the only consistent risk factor for any PN [hazard ratio (HR) 1.785, P=0.0065], grade ≥ 2 PN (HR 2.205, P=0.0032), and grade ≥ 3 PN (HR 2.438, P=0.023); age, pre-existing diabetes, International Staging System stage, obesity, and creatinine clearance did not affect the overall rate of PN. CONCLUSIONS: Rates of bortezomib-induced PN in the frontline setting were similar to those in relapsed patients and resolved in most cases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0609.2010.01533.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 142

Metadata

Authors
Dimopoulos, M. A., Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M., Spicka, I., Palumbo, A., Wu, K. L., Esseltine, D.-L., Liu, K., Deraedt, W., Cakana, A., Van De Velde, H., & San Miguel, J. F.
Venue
European Journal of Haematology
Publisher
Wiley
Published
2010-11-15
Volume
86
Issue
1
Pages
23-31
ISSN
0902-4441 (ISSN-L)
OpenAlex
W1952760452
Cited by
142
References
3
FWCI
7.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study: Reversibility of PN with VMP in newly diagnosed MM. https://app.cochat.ai/papers/10.1111/j.1600-0609.2010.01533.x
The paper
Dimopoulos, M. A., Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M., Spicka, I., Palumbo, A., Wu, K. L., Esseltine, D.-L., Liu, K., Deraedt, W., Cakana, A., Van De Velde, H., & San Miguel, J. F. (2011). Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study: Reversibility of PN with VMP in newly diagnosed MM. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2010.01533.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.